Unichem Laboratories Limited
NSE: UNICHEMLABMarket Closed • NSE
Day range
52 week range
Unichem Laboratories Limited closed at INR510.55 (-2.04%) on volume 0.16x its 20-day average, trading 25.71% below its 52-week high.
2026-Q1
Q1 FY2026 Financial Results
PAT moved -95.9% QoQ
2022-08-01
DIVIDEND Announced
Annual General Meeting/Dividend - Rs 4 Per Share
2021-07-22
DIVIDEND Announced
Annual General Meeting/Dividend - Rs 4 Per Share
Revenue and PAT bars use independent scales to make their year-on-year direction readable.
Complete reported financial history · Values use the company's reporting currency
Hover over the chart for exact reported values. Percentage lines use the right-hand axis.
A 0–100 quantitative summary of reported fundamentals. Use the underlying financials and risks for context; the score is not a buy or sell recommendation.
Strengths
Low Debt Profile: Debt-to-Equity is comfortable at 0.18x
Attractive Valuation: P/E of 11.8x trades below sector historical averages
Risks
Tight Debt Servicing: Interest coverage ratio is under 2.0x
Bull case
Market Leadership: Established operational scale in Drug Manufacturers - Specialty & Generic.
Bear case
Macro Headwinds: Fluctuations in interest rates and sector-specific policy shifts could compress multiples.
Flip condition
Sustained quarterly EBITDA margin expansion above 20% would trigger an upgrade.
Complete dividend, bonus, split, rights and other action history
| Record date | Corporate action | Information | Announcement date | Ex-date |
|---|---|---|---|---|
| — | Dividend | ₹4.00 / share | — | 01 Aug 2022 |
| — | Dividend | ₹4.00 / share | — | 22 Jul 2021 |
| — | Dividend | ₹4.00 / share | — | 20 Aug 2020 |
| — | Dividend | ₹4.00 / share | — | 18 Jul 2019 |
| — | Dividend | ₹5.00 / share | — | 19 Jul 2018 |
| 16 Feb 2018 | Buyback | Buyback | — | 15 Feb 2018 |
| — | Dividend | ₹3.00 / share | — | 13 Jul 2017 |
| — | Annual General Meeting | Annual General Meeting | — | 14 Jul 2016 |
| 19 Mar 2016 | Dividend | ₹2.00 / share | — | 17 Mar 2016 |
| — | Dividend | ₹2.00 / share | — | 02 Jul 2015 |
Traded volume and delivery percentage across the latest 20 sessions
Compare valuation, latest quarterly performance and year-on-year growth
| Company name | Market cap ₹ Cr | P/E ratio | Dividend yield % | Quarterly sales ₹ Cr | Profit after tax ₹ Cr | Sales growth % | Profit growth % |
|---|---|---|---|---|---|---|---|
 Sun Pharmaceutical Industries LimitedSUNPHARMA Open analysis | ₹4.22L | 34.90 | 0.91% | ₹15,300.00 | ₹2,901.00 | +10.46% | +26.52% |
 Divi's Laboratories LimitedDIVISLAB Open analysis | ₹2.43L | 82.97 | 0.33% | ₹3,080.00 | ₹902.00 | +27.80% | +65.50% |
 Torrent Pharmaceuticals LimitedTORNTPHARM Open analysis | ₹1.73L | 72.83 | 0.83% | ₹4,128.00 | ₹389.00 | +41.90% | -21.89% |
 Apollo Hospitals Enterprise LimitedAPOLLOHOSP Open analysis | ₹1.13L | 54.32 | 0.25% | ₹7,044.00 | ₹610.00 | +20.58% | +38.32% |
 Zydus Lifesciences LimitedZYDUSLIFE Open analysis | ₹1.12L | 25.03 | 0.09% | ₹8,017.00 | ₹990.00 | +21.95% | -34.91% |
 LENSKART SOLUTIONS LTDLENSKART Open analysis | ₹1.12L | 174.73 | 0.00% | ₹2,714.00 | ₹228.00 | +43.29% | +273.77% |
 Laurus Labs LimitedLAURUSLABS Open analysis | ₹1.11L | 101.83 | 0.12% | ₹2,026.31 | ₹367.60 | +29.10% | +125.49% |
 Cipla LimitedCIPLA Open analysis | ₹1.07L | 31.78 | 0.98% | ₹7,119.00 | ₹786.00 | +2.33% | -39.16% |
Unichem Laboratories Limited, a pharmaceutical company, manufactures and sells pharmaceutical products in India, the United States, and internationally. The company offers formulation products that address various therapeutic areas, such as gastroenterology, cardiology, diabetology, psychiatry, neurology, anti-bacterial, anti-infective, and pain management. It also offers active pharmaceutical ingredients, as well as contract manufacturing services. In addition, the company manufactures allopathic medicines, bulk drugs, and chemicals. It serves patients, distributors, health care professionals, and government institutions. The company was founded in 1944 and is based in Mumbai, India. Unichem Laboratories Limited is a subsidiary of Ipca Laboratories Limited.
IndiaHealthcare
Is Unichem Laboratories Limited Shariah compliant?
Unichem Laboratories Limited is currently screened as Shariah Compliant under AAOIFI Shariah Standard No. 21. Business activities align with Shariah permissible sectors. Debt to Market Cap (13.91%) complies with AAOIFI threshold (≤ 33%).
What is Unichem Laboratories Limited's current valuation relative to peers?
Unichem Laboratories Limited trades at a P/E of 11.8x compared to the sector median of 37x, and a Price-to-Book of 1.3x.
Is the company financially healthy?
The company has a Debt-to-Equity ratio of 0.18x. Interest coverage is 1.9x.
What are the historical revenue and profit growth rates?
Over the past 5 years, revenue compounded at steady rates while net profit growth averaged consistent levels.
Market data is informational and may be delayed. Shariah screening follows the displayed methodology. This is not investment advice.
Market data may be delayed. Quote date: 2026-10-16. Financial figures relate to their stated reporting periods. This information is for research and is not a recommendation to buy or sell.